These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 26655290)
1. n-3 Fatty acid supplementation and proresolving mediators of inflammation. Barden AE; Mas E; Mori TA Curr Opin Lipidol; 2016 Feb; 27(1):26-32. PubMed ID: 26655290 [TBL] [Abstract][Full Text] [Related]
2. Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. Barden AE; Mas E; Croft KD; Phillips M; Mori TA Am J Clin Nutr; 2015 Dec; 102(6):1357-64. PubMed ID: 26561623 [TBL] [Abstract][Full Text] [Related]
3. Omega-3 Polyunsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? Molfino A; Amabile MI; Monti M; Muscaritoli M Oxid Med Cell Longev; 2017; 2017():5987082. PubMed ID: 28694914 [TBL] [Abstract][Full Text] [Related]
4. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Serhan CN; Libreros S; Nshimiyimana R Semin Immunol; 2022 Jan; 59():101597. PubMed ID: 35227568 [TBL] [Abstract][Full Text] [Related]
6. Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. Elajami TK; Colas RA; Dalli J; Chiang N; Serhan CN; Welty FK FASEB J; 2016 Aug; 30(8):2792-801. PubMed ID: 27121596 [TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Mas E; Barden A; Burke V; Beilin LJ; Watts GF; Huang RC; Puddey IB; Irish AB; Mori TA Clin Nutr; 2016 Apr; 35(2):331-336. PubMed ID: 25908532 [TBL] [Abstract][Full Text] [Related]
8. n - 3 Docosapentaenoic acid: the iceberg n - 3 fatty acid. Ghasemi Fard S; Cameron-Smith D; Sinclair AJ Curr Opin Clin Nutr Metab Care; 2021 Mar; 24(2):134-138. PubMed ID: 33315722 [TBL] [Abstract][Full Text] [Related]
9. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. Keelan JA; Mas E; D'Vaz N; Dunstan JA; Li S; Barden AE; Mark PJ; Waddell BJ; Prescott SL; Mori TA Reproduction; 2015 Feb; 149(2):171-8. PubMed ID: 25504868 [TBL] [Abstract][Full Text] [Related]
10. Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. Barden A; Mas E; Croft KD; Phillips M; Mori TA J Lipid Res; 2014 Nov; 55(11):2401-7. PubMed ID: 25187667 [TBL] [Abstract][Full Text] [Related]
11. Effects of prenatal n-3 fatty acid supplementation on offspring resolvins at birth and 12 years of age: a double-blind, randomised controlled clinical trial. See VHL; Mas E; Prescott SL; Beilin LJ; Burrows S; Barden AE; Huang RC; Mori TA Br J Nutr; 2017 Dec; 118(11):971-980. PubMed ID: 29173199 [TBL] [Abstract][Full Text] [Related]
12. The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease. Barden AE; Shinde S; Burke V; Puddey IB; Beilin LJ; Irish AB; Watts GF; Mori TA Prostaglandins Other Lipid Mediat; 2018 May; 136():1-8. PubMed ID: 29577973 [TBL] [Abstract][Full Text] [Related]
13. Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis. Salazar J; Pirela D; Nava M; Castro A; Angarita L; Parra H; Durán-Agüero S; Rojas-Gómez DM; Galbán N; Añez R; Chacín M; Diaz A; Villasmil N; De Sanctis JB; Bermúdez V Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328553 [TBL] [Abstract][Full Text] [Related]
14. Polyunsaturated fatty acids, specialized pro-resolving mediators, and targeting inflammation resolution in the age of precision nutrition. Al-Shaer AE; Buddenbaum N; Shaikh SR Biochim Biophys Acta Mol Cell Biol Lipids; 2021 Jul; 1866(7):158936. PubMed ID: 33794384 [TBL] [Abstract][Full Text] [Related]
15. Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome. Kwon Y Mol Nutr Food Res; 2020 Feb; 64(4):e1900824. PubMed ID: 31797565 [TBL] [Abstract][Full Text] [Related]
16. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Calder PC Biochimie; 2020 Nov; 178():105-123. PubMed ID: 32860894 [TBL] [Abstract][Full Text] [Related]
17. The roles of special proresolving mediators in pain relief. Zhang LY; Jia MR; Sun T Rev Neurosci; 2018 Aug; 29(6):645-660. PubMed ID: 29420307 [TBL] [Abstract][Full Text] [Related]
18. Lipids in critical care medicine. Ott J; Hiesgen C; Mayer K Prostaglandins Leukot Essent Fatty Acids; 2011 Nov; 85(5):267-73. PubMed ID: 21546231 [TBL] [Abstract][Full Text] [Related]
19. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Radbakhsh S; Katsiki N; Santos RD; Mikhailidis DP; Mantzoros CS; Sahebkar A Metabolism; 2022 Jul; 132():155211. PubMed ID: 35533891 [TBL] [Abstract][Full Text] [Related]
20. Specialized pro-resolving mediator network: an update on production and actions. Chiang N; Serhan CN Essays Biochem; 2020 Sep; 64(3):443-462. PubMed ID: 32885825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]